Accuray Europe and GE Capital Healthcare Equipment Finance signed a collaboration agreement to develop sustainable financing options that will increase market access to the CyberKnife and TomoTherapy systems. These solutions provide excellent treatment outcomes for a wide range of cancerous and non-cancerous tumors.

The new financing program will make it even easier for clinicians throughout Europe to offer their patients a non-invasive treatment option that delivers precise radiation therapy while maximizing patients’ quality of life during and after treatment.

“In today’s complex global healthcare environment, it’s important to keep the needs of physicians and their patients top-of-mind. The new financing program with GE Capital Healthcare Equipment Finance underscores our commitment to providing the cancer community with world-class options for accessing and treating cancer,” said Lionel Hadjadjeba, senior vice president, worldwide commercial operations of Accuray.

The Accuray and GE Capital Healthcare Equipment Finance collaboration enables hospitals, clinics and medical practitioners to lease Accuray equipment and services through a turnkey offering that combines bunker construction, hardware, software, services and ongoing maintenance costs into one finance agreement. The aim is to provide a flexible and sustainable funding solution for healthcare investments that make it possible for clinicians and patients to access Accuray’s precise, novel tumor treatments.

“Our financing solutions aim at making life-saving technology more accessible to healthcare institutions, helping them provide superior clinical care and allowing them to focus their resources where it matters most to patients,” added Christian Bernhard, general manager, GE Capital Healthcare Equipment Finance in Europe.

Accuray is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives.